Pharmacy benefit manager shares dropped sharply Wednesday as lawmakers introduced bipartisan legislation requiring health insurers and PBMs to divest pharmacy operations within three years. The proposal intensifies scrutiny of the PBM industry's influence over drug pricing.
Bipartisan Bill Targets Vertical Integration in Healthcare
According to Reuters, following the presentation of a bipartisan measure on Wednesday, which would compel health insurers or drug intermediaries to sell off their pharmacy businesses, shares of companies owning pharmacy benefit managers declined.
The majority of pharmacy benefit management (PBM) in the US is controlled by CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum. All three of these parent firms also own health insurance businesses.
Following the initial reporting of the bill in the Wall Street Journal, all three firms' shares fell by 4.8% to 5.5%.
The bill, which is being co-sponsored by Republican Josh Hawley and Democratic Elizabeth Warren in the United States Senate, would require, within three years, that companies that own health insurers or pharmacy benefit managers sell their shares in pharmacies.
Healthcare Stocks React to Bipartisan Proposal
This bill will be submitted in Congress with the support of Republican Diana Harshbarger and Democratic Jake Auchincloss.
Pharmacy benefit managers (PBMs) mediate pricing negotiations for prescription prescriptions between insurance companies, pharmacies, and pharmaceutical companies. PBMs then pay pharmacies directly for the medications covered by their contracts.
They have already been investigated for the impact they have on the cost of prescription drugs.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business. My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen," Senator Warren stated.
Other Insurers Feel the Ripple Effect of PBM Legislation
Other insurance companies' stock prices dropped 1% to 3%. This included Centene, Elevance, and Humana, Investing.com shares.
"The latest introduction of potential legislation to restrict PBM operations and broader healthcare vertical integration is unlikely to gain traction, although it is hard to dismiss outright," Michael Cherny, an analyst at Leerink Partners, said.
Insurance company stock has taken a beating following last week's shooting death of UnitedHealth health insurance unit CEO Brian Thompson outside a Manhattan hotel.


Continental AG Shares Jump After Q1 Profit Beats Expectations
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data
Gold Prices Rise as Weaker Dollar and Iran Ceasefire Hopes Boost Safe-Haven Demand
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia
Japan Tech Stocks Surge as AI Optimism Lifts SoftBank, Chipmakers
Wall Street Futures Edge Higher as Iran Tensions and AI Optimism Shape Markets
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone
Lula and Trump Talks Signal New Phase in Brazil-US Relations
Iran-U.S. Peace Deal Near as Oil Prices Fall and Nuclear Disputes Persist
Dollar Struggles to Rally Despite Strong US Data as Fed Hike Expectations Remain Limited
Gold Prices Hold Firm as Iran Tensions and Dollar Swings Drive Safe-Haven Demand
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says
Trump Signals Possible U.S.-Iran Peace Deal as Markets Rally on Hopes of War Ending 



